Skip to main content
INBX logo
INBX
(NASDAQ)
Inhibrx Biosciences, Inc.
$85.00-- (--)
Loading... - Market loading

Inhibrx Biosciences (INBX) Key Statistics & Financial Metrics

Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Market Valuation & Earnings Multiples

Market capitalization, P/E ratios, and enterprise value

Market Cap1.32B
Enterprise Value1.17B

Price-Based Ratios

Valuation ratios based on stock price

Price/Sales (ttm)1019.02
Forward Price/Sales339.67
Price/Book (mrq)-62.98

Enterprise Value Ratios

EV-based valuation multiples

EV/Revenue899.21
EV/Earnings-8.98
EV/EBITDA-10.09
EV/EBIT-8.98
EV/FCF-8.86

Stock Price

Current price, 52-week range, and moving averages

Current Price$85.00
1-Day Change-1.07%
52-Week High$155.29
52-Week Low$20.55
52-Week Change266.38%
YTD Change13.27%
1-Year Change268.44%
50-Day MA$96.84
200-Day MA$82.36
Avg Volume (30 day)329.72K

Share Statistics

Outstanding shares, float, and per-share metrics

Shares Outstanding15.59M
Book Value per Share$-1.35
Net Cash per Share$9.99
FCF per Share$-8.47

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Profit Margins

Profitability margins across income statement

Gross Margin7.77%
EBITDA Margin (ttm)-8909.00%
EBIT Margin (ttm)-10010.46%
Operating Margin (ttm)-9465.46%
Pretax Margin (ttm)-10014.08%
Profit Margin (ttm)-10014.23%
FCF Margin (ttm)-10148.85%

Return on Investment Metrics

ROE, ROA, ROIC, and capital efficiency ratios

Return on Assets (ttm)-70.77%
Return on Capital Employed (ttm)-82.65%

Income Statement (TTM)

Trailing twelve months revenue and earnings

Revenue1.30M
Gross Profit101.00K
Operating Income-123.05M
Pretax Income-130.18M
Net Income-130.19M
EBITDA-115.82M
EBIT-130.14M
Diluted EPS$-8.39

Cash Flow (TTM)

Operating cash flow and free cash flow metrics

Operating Cash Flow-131.93M
Capital Expenditures10.00K
Free Cash Flow-131.94M

Growth Rates (YoY)

Year-over-year growth metrics

Revenue Growth550.00%

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Assets & Cash

Total assets and cash positions

Total Assets (mrq)183.97M
Cash & Securities (mrq)161.66M
Net Cash (mrq)155.75M
Net Cash per Share$9.99

Debt & Liabilities

Liabilities, debt, equity, and working capital

Total Debt (mrq)5.90M
Working Capital (mrq)144.83M
Total Equity (mrq)-21.04M
Book Value per Share$-1.35

Liquidity & Leverage

Liquidity, leverage, and debt coverage ratios

Current Ratio (mrq)6.46
Quick Ratio (mrq)6.46

Dividend History & Payout Analysis

Dividend yield, payout ratios, and growth metrics

Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Ex-Dividend DateMay 30, 2024
Pay DateJun 20, 2024

Yield Metrics

Earnings, FCF, buyback, and shareholder yields

Earnings Yield-9.83%
FCF Yield-9.96%
Buyback Yield-0.13%
Total Shareholder Yield-0.13%

Financial Health Scores

Risk assessment and quality metrics

Altman Z-Score-4.65
Piotroski F-Score2/9

Frequently Asked Questions About Inhibrx Biosciences Statistics

What are the key financial metrics for INBX?

Inhibrx Biosciences, Inc. (INBX) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is INBX's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Inhibrx Biosciences is overvalued or undervalued.

How do I read INBX's profitability ratios?

Inhibrx Biosciences's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do INBX's debt ratios indicate?

The financial health section shows Inhibrx Biosciences's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is INBX's dividend analysis?

The dividend section covers Inhibrx Biosciences's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.